NIDDK director Rodgers to speak at Duke 10/22/2012
By etm18@dhe.duke.edu
Griffin P. Rodgers, MD, director of the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), will discuss the "In Vitro model for studying lineage-specific differentiation and plasticity of hematopoietic stem cells" Mon., Oct. 22 at 5 p.m. in the Searle Center.
"Dr. Rodgers is responsible for steering NIDDK to stimulate the most productive, innovative avenues of research," said Marilyn Telen, MD, chief of the Division of Hematology. "To that end, he is looking for where the best new scientific talent is, and what ideas are coming to the surface. So while I expect that his talk will explain his own ideas for the NIDDK research agenda, I also expect that he will also be listening carefully to his audience. For both reasons, investigators in all fields relevant to the NIDDK should attend his talk."
As a research investigator, Rodgers was principal investigator in clinical trials to develop therapy for patients with sickle cell disease, and he conducted research that focused on the molecular basis of how certain drugs induce gamma-globin gene expression.
"He is an outstanding physician-scientist and molecular hematologist who has made important contributions to our understanding of hemoglobinopathies and the pathophysiologic mechanisms affecting patients with these disorders," Telen said.
Rodgers holds undergraduate, graduate and medical degrees from Brown University and performed his residency and chief residency at Barnes Hospital and the Washington University School of Medicine in St. Louis. In 2005, he earned a master's degree in business administration, with a focus in the business of medicine, from Johns Hopkins University. Rodgers has been NIDDK director since 2007.
Griffin P. Rodgers, MD, director of the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), will discuss the "In Vitro model for studying lineage-specific differentiation and plasticity of hematopoietic stem cells" Mon., Oct. 22 at 5 p.m. in the Searle Center.
"Dr. Rodgers is responsible for steering NIDDK to stimulate the most productive, innovative avenues of research," said Marilyn Telen, MD, chief of the Division of Hematology. "To that end, he is looking for where the best new scientific talent is, and what ideas are coming to the surface. So while I expect that his talk will explain his own ideas for the NIDDK research agenda, I also expect that he will also be listening carefully to his audience. For both reasons, investigators in all fields relevant to the NIDDK should attend his talk."
As a research investigator, Rodgers was principal investigator in clinical trials to develop therapy for patients with sickle cell disease, and he conducted research that focused on the molecular basis of how certain drugs induce gamma-globin gene expression.
"He is an outstanding physician-scientist and molecular hematologist who has made important contributions to our understanding of hemoglobinopathies and the pathophysiologic mechanisms affecting patients with these disorders," Telen said.
Rodgers holds undergraduate, graduate and medical degrees from Brown University and performed his residency and chief residency at Barnes Hospital and the Washington University School of Medicine in St. Louis. In 2005, he earned a master's degree in business administration, with a focus in the business of medicine, from Johns Hopkins University. Rodgers has been NIDDK director since 2007.